Jasper Therapeutics Inc Ordinary Shares JSPR
News
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $14.08
- Day Range
- $13.20–13.75
- 52-Week Range
- $9.50–72.30
- Bid/Ask
- $13.70 / $14.30
- Shares Outstanding
- 1.11M
- Market Cap
- $520,414.12
- Volume/Avg
- 766 / 16,632
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
Valuation
Metric | JSPR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.32 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
JSPR
Financial Strength
Metric | JSPR |
|---|---|
Quick Ratio | 0.93 |
Current Ratio | 1.47 |
Interest Coverage | — |
Quick Ratio
JSPR
Profitability
Metric | JSPR |
|---|---|
Return on Assets (Normalized) | −143.74% |
Return on Equity (Normalized) | −563.71% |
Return on Invested Capital (Normalized) | −504.16% |
Return on Assets
JSPR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|QFJgV^ | LOCK|F<wNB | $138B | |||
| Moderna Inc MRNA | LOCK|hkB&gx | LOCK|@Sl | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|N$^d<& | LOCK|btk<R | $93B | |||
| argenx SE ADR ARGX | LOCK|$&k&># | LOCK|?C | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#%$w%Ml | LOCK|@LF | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>^QLxWs | LOCK|!nQr | $30B | |||
| Incyte Corp INCY | LOCK|ZCQ&?pb | LOCK|h$X | $24B | |||
| BioNTech SE ADR BNTX | LOCK|gp%>jP | LOCK|!s | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Vm&JP< | LOCK|hmt>W | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|d&&HfQ< | LOCK|G<> | $15B |
United States